Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An announcement from ARS Pharmaceuticals (SPRY) is now available.
ARS Pharmaceuticals, Inc. announces FDA approval of neffy®, an epinephrine nasal spray for emergency treatment of severe allergic reactions in individuals over 30 kg. Based on robust clinical trial data, neffy is expected to hit the U.S. market within eight weeks, with plans to extend its use to lighter children later in the year. Meanwhile, a positive European opinion suggests a potential EU launch in the fourth quarter. Investors should note these forward-looking statements carry risks, as actual results may vary due to multiple factors, including regulatory changes and market acceptance.
For an in-depth examination of SPRY stock, go to TipRanks’ Stock Analysis page.
